%0 Journal Article
%A Jahn, Arne
%A Rump, A.
%A Widmann, Thomas
%A Heining, Christoph
%A Horak, Peter
%A Hutter, Barbara
%A Paramasivam, Nagarajan
%A Uhrig, Sebastian
%A Gieldon, L.
%A Drukewitz, Stephan
%A Kübler, A.
%A Bermudez, M.
%A Hackmann, K.
%A Porrmann, J.
%A Wagner, J.
%A Arlt, M.
%A Franke, M.
%A Fischer, J.
%A Kowalzyk, Z.
%A William, Doreen
%A Weth, V.
%A Oster, Sandra
%A Fröhlich, Martina Antonia
%A Hüllein, Jennifer
%A Valle González, C.
%A Kreutzfeldt, Simon
%A Mock, Andreas
%A Heilig, Christoph
%A Lipka, Daniel
%A Möhrmann, Lino
%A Hanf, Dorothea
%A Teleanu, Maria-Veronica
%A Allgäuer, M.
%A Ruhnke, L.
%A Kutz, O.
%A Knurr, Alexander
%A Laßmann, Andreas
%A Endris, V.
%A Neumann, O.
%A Penzel, R.
%A Beck, Katja
%A Richter, Daniela
%A Winter, Ulrike
%A Wolf, Stephan
%A Pfütze, Katrin
%A Geörg, Christina
%A Meissburger, Bettina
%A Buchhalter, Ivo
%A Augustin, M.
%A Aulitzky, W. E.
%A Hohenberger, P.
%A Kroiss, M.
%A Schirmacher, Peter
%A Schlenk, Richard
%A Keilholz, Ulrich
%A Klauschen, F.
%A Folprecht, G.
%A Bauer, S.
%A Siveke, Jens
%A Brandts, C. H.
%A Kindler, T.
%A Börries, Melanie
%A Illert, A. L.
%A von Bubnoff, N.
%A Jost, P. J.
%A Metzeler, K. H.
%A Bitzer, M.
%A Schulze Osthoff, Klaus
%A von Kalle, C.
%A Brors, Benedikt
%A Stenzinger, A.
%A Weichert, Wilko
%A Hübschmann, Daniel
%A Fröhling, Stefan
%A Glimm, Hanno
%A Schröck, E.
%A Klink, B.
%T Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
%J Annals of oncology
%V 33
%N 11
%@ 0923-7534
%C Amsterdam [u.a.
%I Elsevier
%M DKFZ-2022-01948
%P 1186-1199
%D 2022
%Z 2022 Nov;33(11):1186-1199
%X Germline variant evaluation in precision oncology opens new paths towards the identification of patients with genetic tumor risk syndromes and the exploration of therapeutic relevance. Here, we present the results of germline variant analysis and their clinical implications in a precision oncology study for patients with predominantly rare cancers.Matched tumor and control genome/exome and RNA sequencing was performed for 1,485 patients with rare cancers (79
%K biomarker (Other)
%K hereditary cancer (Other)
%K precision medicine (Other)
%K prevention (Other)
%K rare cancer (Other)
%K targeted therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35988656
%R 10.1016/j.annonc.2022.07.008
%U https://inrepo02.dkfz.de/record/181321